scholarly journals Postexercise Glycemic Control in Type 1 Diabetes Is Associated With Residual β-Cell Function

Diabetes Care ◽  
2020 ◽  
Vol 43 (10) ◽  
pp. 2362-2370 ◽  
Author(s):  
Guy S. Taylor ◽  
Kieran Smith ◽  
Tess E. Capper ◽  
Jadine H. Scragg ◽  
Ayat Bashir ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Glycemic Control ◽  
Cell Function ◽  
Β Cell ◽  
Β Cell Function

scholarly journals Residual β-Cell Function More than Glycemic Control Determines Abnormalities of the Insulin-Like Growth Factor System in Type 1 Diabetes

2004 ◽  
Vol 89 (12) ◽  
pp. 6305-6309 ◽  
Author(s):  
Christina A. Hedman ◽  
Jan Frystyk ◽  
Torbjörn Lindström ◽  
Jian-Wen Chen ◽  
Allan Flyvbjerg ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Glycemic Control ◽  
Cell Function ◽  
Β Cell ◽  
Good Glycemic Control ◽  
C Peptide ◽  
Igf I ◽  
Β Cell Function ◽  
Igfbp 3

Abstract The GH-IGF-I axis is disturbed in patients with type 1 diabetes. Our aim was to investigate whether abnormalities are found in patients in very good glycemic control and, if so, to estimate the role of residual β-cell function. Patients with hemoglobin A1c (HbA1c) less than 6% (reference range, 3.6–5.4%) were selected for the study. Twenty-two men and 24 women, aged 41.3 ± 13.8 yr (mean ± sd), with a diabetes duration of 17.8 ± 14.6 yr participated. Healthy controls (15 women and nine men), aged 41.3 ± 13.0 yr, were also studied. Overnight fasting serum samples were analyzed for HbA1c, C peptide, free and total IGFs, IGF-binding proteins (IGFBPs), GH-binding protein, and IGFBP-3 proteolysis. HbA1c was 5.6 ± 0.5% in patients and 4.4 ± 0.3% in controls. Total IGF-I was 148 ± 7 μg/liter in patients and 178 ± 9 μg/liter in controls (P < 0.001). Free IGF-I, total IGF-II, IGFBP-3, and GH-binding protein were lower, whereas IGFBP-1, IGFBP-1-bound IGF-I, and IGFBP-2 were elevated compared with control values. Patients with detectable C peptide (≥100 pmol/liter) had higher levels of total IGF-I, free IGF-I, and total IGF-II and lower levels of IGFBP-1 and IGFBP-2 than those with an undetectable C peptide level despite having identical average HbA1c. IGFBP-3 proteolysis did not differ between patients and controls. Despite very good glycemic control, patients with type 1 diabetes and no endogenous insulin production have low free and total IGF-I. Residual β-cell function, therefore, seems more important for the disturbances in the IGF system than good metabolic control per se, suggesting that portal insulin delivery is needed to normalize the IGF system.

Insulin Pump Therapy Started at the Time of Diagnosis: Effects on Glycemic Control and Pancreatic β-Cell Function in Type 1 Diabetes

2011 ◽  
Vol 13 (10) ◽  
pp. 1023-1030 ◽  
Author(s):  
Kathryn M. Thrailkill ◽  
Cynthia S. Moreau ◽  
Christopher Swearingen ◽  
Mallik Rettiganti ◽  
Kathy Edwards ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Glycemic Control ◽  
Cell Function ◽  
Insulin Pump ◽  
Insulin Pump Therapy ◽  
Pancreatic Β Cell ◽  
Β Cell ◽  
Pump Therapy ◽  
Β Cell Function

scholarly journals Relationship of continuous glucose monitoring-related metrics with HbA1c and residual β-cell function in Japanese patients with type 1 diabetes

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Naru Babaya ◽  
Shinsuke Noso ◽  
Yoshihisa Hiromine ◽  
Yasunori Taketomo ◽  
Fumimaru Niwano ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Glycemic Control ◽  
Cell Function ◽  
Glucose Monitoring ◽  
Japanese Patients ◽  
Β Cell ◽  
Glucose Levels ◽  
Β Cell Function ◽  
Average Glucose

AbstractThe targets for continuous glucose monitoring (CGM)-derived metrics were recently set; however, studies on CGM data over a long period with stable glycemic control are limited. We analyzed 194,279 CGM values obtained from 19 adult Japanese patients with type 1 diabetes. CGM data obtained during stable glycemic control over four months were analyzed. CGM-related metrics of different durations “within 120, 90, 60, 30, and 7 days” were calculated from baseline. Time in range (TIR; glucose 70–180 mg/dL), time above range (TAR; glucose ≥ 181 mg/dL), and average glucose levels, but not time below range (TBR; glucose ≤ 69 mg/dL), strongly correlated with glycated hemoglobin (HbA1c) values (P < 0.0001). TBR correlated with glucose coefficient of variation (CV) (P < 0.01). Fasting serum C-peptide levels negatively correlated with glucose CV (P < 0.01). HbA1c of approximately 7% corresponded to TIR of 74% and TAR of 20%. The shorter the CGM period, the weaker was the relationship between HbA1c and CGM-related metrics. TIR, TAR, and average glucose levels accurately reflected HbA1c values in Japanese patients with type 1 diabetes with stable glycemic control. Glucose CV and TBR complemented the limitation of HbA1c to detect glucose variability and hypoglycemia. Stable glycemic control with minimal hypoglycemia depended on residual β-cell function.

Association of T-cell reactivity with β-cell function in recent onset type 1 diabetes patients

2010 ◽  
Vol 34 (2) ◽  
pp. 127-135 ◽  
Author(s):  
Christian Pfleger ◽  
Guido Meierhoff ◽  
Hubert Kolb ◽  
Nanette C. Schloot
Keyword(s):  
Type 1 Diabetes ◽  
T Cell ◽  
Cell Function ◽  
Β Cell ◽  
Cell Reactivity ◽  
Recent Onset ◽  
Onset Type ◽  
Β Cell Function ◽  
T Cell Reactivity

scholarly journals Autoreactive T effector memory differentiation mirrors β cell function in type 1 diabetes

2018 ◽  
Vol 128 (8) ◽  
pp. 3460-3474 ◽  
Author(s):  
Lorraine Yeo ◽  
Alyssa Woodwyk ◽  
Sanjana Sood ◽  
Anna Lorenc ◽  
Martin Eichmann ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Cell Function ◽  
Effector Memory ◽  
Β Cell ◽  
Β Cell Function ◽  
Memory Differentiation

scholarly journals Residual β-cell function after 10 years of autoimmune type 1 diabetes: prevalence, possible determinants, and implications for metabolism

2021 ◽  
Vol 9 (8) ◽  
pp. 650-650
Author(s):  
Jin Cheng ◽  
Min Yin ◽  
Xiaohan Tang ◽  
Xiang Yan ◽  
Yuting Xie ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Cell Function ◽  
Diabetes Prevalence ◽  
Β Cell ◽  
Β Cell Function

scholarly journals Systemic TNFα correlates with residual β-cell function in children and adolescents newly diagnosed with type 1 diabetes

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Anne Julie Overgaard ◽  
Jens Otto Broby Madsen ◽  
Flemming Pociot ◽  
Jesper Johannesen ◽  
Joachim Størling
Keyword(s):  
Type 1 Diabetes ◽  
Cell Function ◽  
Disease Onset ◽  
Newly Diagnosed ◽  
Β Cell ◽  
Entire Study ◽  
C Peptide ◽  
Disease Remission ◽  
Β Cell Function

Abstract Background Type 1 diabetes (T1D) is caused by immune-mediated destruction of the β-cells. After initiation of insulin therapy many patients experience a period of improved residual β-cell function leading to partial disease remission. Cytokines are important immune-modulatory molecules and contribute to β-cell damage in T1D. The patterns of systemic circulating cytokines during T1D remission are not clear but may constitute biomarkers of disease status and progression. In this study, we investigated if the plasma levels of various pro- and anti-inflammatory cytokines around time of diagnosis were predictors of remission and residual β-cell function in children with T1D followed for one year after disease onset. Methods In a cohort of 63 newly diagnosed children (33% females) with T1D with a mean age of 11.3 years (3.3–17.7), ten cytokines were measured of which eight were detectable in plasma samples by Mesoscale Discovery multiplex technology at study start and after 6 and 12 months. Linear regression models were used to evaluate association of cytokines with stimulated C-peptide. Results Systemic levels of tumor necrosis factor (TNF)-α, interleukin (IL)-2 and IL-6 inversely correlated with stimulated C-peptide levels over the entire study (P < 0.05). The concentrations of TNFα and IL-10 at study start predicted stimulated C-peptide level at 6 months (P = 0.011 and P = 0.043, respectively, adjusted for sex, age, HbA1c and stage of puberty). Conclusions In recent-onset T1D, systemic cytokine levels, and in particular that of TNFα, correlate with residual β-cell function and may serve as prognostic biomarkers of disease remission and progression to optimize treatment strategies. Trial Registration The study was performed according to the criteria of the Helsinki II Declaration and was approved by the Danish Capital Region Ethics Committee on Biomedical Research Ethics (journal number H-3-2014-052). The parents of all participants gave written consent.

scholarly journals Exercise to preserve β-cell function in recent-onset Type 1 diabetes mellitus (EXTOD) - a randomized controlled pilot trial

2017 ◽  
Vol 34 (11) ◽  
pp. 1521-1531 ◽  
Author(s):  
P. Narendran ◽  
N. Jackson ◽  
A. Daley ◽  
D. Thompson ◽  
K. Stokes ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Cell Function ◽  
Pilot Trial ◽  
Β Cell ◽  
Recent Onset ◽  
Randomized Controlled ◽  
Β Cell Function

scholarly journals Preserved β-Cell Function in Type 1 Diabetes by Mesenchymal Stromal Cells

Diabetes ◽  
2014 ◽  
Vol 64 (2) ◽  
pp. 587-592 ◽  
Author(s):  
Per-Ola Carlsson ◽  
Erik Schwarcz ◽  
Olle Korsgren ◽  
Katarina Le Blanc
Keyword(s):  
Type 1 Diabetes ◽  
Mesenchymal Stromal Cells ◽  
Stromal Cells ◽  
Cell Function ◽  
Β Cell ◽  
Β Cell Function
Sign in / Sign up

Export Citation Format

Share Document